Cochrane · systematic review · CD006866
Antiviral treatment for preventing postherpetic neuralgia
Chen, N, Li, Q, Yang, J, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 3 · 100%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oral aciclovir for acute herpes zoster to prevent postherpetic neuralgia (PHN)
Population: people with acute herpes zoster1
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Presence of PHN 6 months after the onset of the acute herpetic rash2 Clinical diagnostic criteria for PHN in any intensity | no estimate extracted | 2 studies · 476 participants | High |
Presence of PHN 4 months after the onset of the acute herpetic rash Clinical diagnostic criteria for PHN in any intensity | RR 0.75 [0.51, 1.11] | 3 studies · 609 participants | High |
Adverse events Clinical manifestations | RR 1.01 [0.88, 1.15] | 4 studies · 709 participants | High |